{"id":"W2947706849","doi":"10.1186/s13063-019-3346-z","title":"MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis","year":2019,"lang":"en","type":"article","venue":"Trials","topic":"Mesenchymal stem cell research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Sanofi Genzyme; Paracelsus Medizinische Privatuniversität; Multiple Sclerosis International Federation; AFM-Téléthon; Imperial College London; European Committee for Treatment and Research in Multiple Sclerosis; Multiple Sclerosis Society; Scleroseforeningen; Toyota Foundation; Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques; Teva Pharmaceutical Industries; National Institute for Health and Care Research; Sanofi; Danmarks Frivillige Bloddonorer; Fondazione Italiana Sclerosi Multipla; Biogen","keywords":"Mesenchymal stem cell; Medicine; Multiple sclerosis; Stem cell; Stem-cell therapy; Clinical trial; Pathology; Immunology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0353532,0.001063834,0.006862885,0.0004357905,0.0006729263,0.000302506,0.001249033,0.001002948,0.0008733958],"category_scores_gemma":[0.002304816,0.0006066572,0.003467171,0.0008026831,0.001191662,0.0003620312,0.0003274402,0.0008894771,0.0001075612],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000196139,"about_ca_system_score_gemma":0.001421548,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004878109,"about_ca_topic_score_gemma":0.00006816625,"domain_scores_codex":[0.9860283,0.002635999,0.005470527,0.001850873,0.002229242,0.001785065],"domain_scores_gemma":[0.9383052,0.05462603,0.002686763,0.002233006,0.001410595,0.0007383872],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8619418,0.003098664,0.0008115835,0.0003679118,0.002302247,0.000006013339,0.000510678,0.0001955645,0.1084313,0.0001051387,0.002724501,0.01950458],"study_design_scores_gemma":[0.708504,0.01275049,0.00007516745,0.0002863781,0.0007436526,0.000005779016,0.0002618351,0.006713174,0.2640057,0.00001511024,0.006134526,0.0005041636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9204807,0.001777851,0.002640703,0.0005367802,0.003110576,0.07037634,0.0006895367,0.0001604918,0.0002269824],"genre_scores_gemma":[0.9792131,0.001326172,0.002105809,0.0002042707,0.001959041,0.006422104,0.00006900247,0.0002511251,0.008449435],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1555744,"threshold_uncertainty_score":0.9996385,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.43771613823638,"score_gpt":0.462930422822696,"score_spread":0.02521428458631597,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}